State ADAPs secure higher Rx discounts
Executive Summary
Abbott, Boehringer Ingelheim, Gilead and Merck agree to price concessions for state AIDS drug assistance programs. Abbott agreement provides supplemental rebates on full HIV/AIDS product line; BI says it will freeze Viramune price for two years. Companies join Roche in finalizing negotiations following Washington, D.C. meeting (1"The Pink Sheet" April 21, p. 7). Discussions with Pfizer/Agouron, GlaxoSmithKline and Bristol-Myers Squibb are ongoing, state directors say...
You may also be interested in...
Bristol at impasse with ADAPs
Negotiations between Bristol-Myers Squibb and coalition of state AIDS Drug Assistance Program directors has "stalled," Treatment Action Group Representative Robert Camp says during Bristol Reyataz advisory committee meeting. "I am here to express profound disappointment at BMS' failure to negotiate serious price discounts and freezes in good faith with state and territorial ADAP directors." Bristol is one of three HIV therapy manufacturers who has not yet reached an agreement with the state AIDS program; other companies include Pfizer/Agouron and GlaxoSmithKline (1"The Pink Sheet" April 28, In Brief)...
State ADAPs Ask Manufacturers For Price Concessions; Fuzeon Fuels Effort
State AIDS Drug Assistance Programs are asking all HIV therapy manufacturers for price breaks as they prepare to pick up coverage of Roche's Fuzeon
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.